E. B. Hookfin

Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors.

A. Freemont, J. Woessner, J. Hoyland, 2001, Osteoarthritis and cartilage.

Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis

Bo Peng, T. Baker, M. Natchus, 2006, Inflammation Research.

Detection of aggrecanase- and MMP-generated catabolic neoepitopes in the rat iodoacetate model of cartilage degeneration.

A. Poole, C. Little, B. Caterson, 2004, Osteoarthritis and cartilage.

Isolation and quantification of fluoroacetate in rat tissues, following dosing of Z-Phe-Ala-CH2-F, a peptidyl fluoromethyl ketone protease inhibitor.

K. Wehmeyer, B. De, Y. Taiwo, 1997, Journal of pharmaceutical and biomedical analysis.

P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis

S. Heitmeyer, M. J. Janusz, L. Hsieh, 2008, Journal of Inflammation.

Quantitative imaging of proteoglycan in cartilage using a gadolinium probe and microCT.

T. Dufresne, P. Chmielewski, E. B. Hookfin, 2006, Osteoarthritis and cartilage.

P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis

M. J. Janusz, L. Hsieh, M. Buchalova, 2008, Journal of Inflammation.

Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.

T. Baker, M. Dowty, M. Natchus, 2000, Journal of medicinal chemistry.